Australia's most trusted
source of pharma news
Posted 6 December 2021 AM
Over the past week, the TGA approved three new medicines, including Pfizer's Ngenla which will be considered for government-subsidy for paediatric growth hormone deficiency at the PBAC's first meeting in the new year.
Ngenla, a once-weekly, long-acting, recombinant human growth hormone, marks one of the first in a long list of medicines submitted to the committee's March meeting under parallel processing that have been TGA approved.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.